Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer
Φόρτωση...
Ημερομηνία
Συγγραφείς
Aravantinos, G.
Dimopoulos, M. A.
Kosmidis, P.
Bafaloukos, D.
Papadimitriou, C.
Kiamouris, C.
Pavlidis, N.
Sikiotis, K.
Papakostas, P.
Skarlos, D. V.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Ann Oncol
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
BACKGROUND: The prognosis of platinum resistant ovarian cancer is very poor and the treatment of choice has not been clearly defined. PATIENTS AND METHODS: We conducted a phase II study with the combination of ifosfamide i.v. at 2.25 g/m2 (days 1, 2) and etoposide per os at 100 mg daily (days 1-10) every four weeks. To be eligible for the study patients had to be resistant to platinum and paclitaxel pretreated. RESULTS: Forty-one patients entered the study. The median interval from the previous chemotherapy was 3.9 months. The median number of previous chemotherapeutic regimens was 2. Severe toxicities included neutropenia (41% of patients), leukopenia (29%) and thrombocytopenia (13%). Thirty-five patients are assessable for response. Nine patients responded (22% of the eligible, 26% of the assessable), four of them demonstrated complete response to chemotherapy (10% and 12%, respectively), while three patients demonstrated stabilization of their progressive disease. After a median follow-up of 18 months, time to progression is 3 months (range 0.9-14.4), duration of response is 9 months (2.5-11) and median survival is 13 months (2.5-37.4+). CONCLUSIONS: The combination of ifosfamide with oral etoposide appears to have significant but manageable toxicity and encouraging efficacy in platinum resistant ovarian cancer.
Περιγραφή
Λέξεις-κλειδιά
Administration, Oral, Adult, Aged, Antineoplastic Agents, Phytogenic/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/administration &, dosage/*therapeutic use, Disease Progression, Drug Resistance, Neoplasm, Etoposide/administration & dosage, Female, Humans, Ifosfamide/administration & dosage, Infusions, Intravenous, Middle Aged, Ovarian Neoplasms/*drug therapy/pathology, Paclitaxel/pharmacology, Prognosis, Salvage Therapy, Survival Analysis
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/10907957
http://annonc.oxfordjournals.org/content/11/5/607.full.pdf
http://annonc.oxfordjournals.org/content/11/5/607.full.pdf
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής